Clinical Trials Logo

Classical Hodgkin Lymphoma clinical trials

View clinical trials related to Classical Hodgkin Lymphoma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT02824029 Active, not recruiting - Clinical trials for Classical Hodgkin Lymphoma

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Start date: June 2016
Phase: Phase 2
Study type: Interventional

This phase II trial evaluates how effective 560 mg of ibrutinib taken by mouth daily is in the treatment of classical Hodgkin lymphoma which recurs or does not respond to initial treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, by altering the environment around the tumor or by affecting the immune system.

NCT ID: NCT02684708 Active, not recruiting - Clinical trials for Classical Hodgkin Lymphoma

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Start date: October 1, 2015
Phase: Phase 3
Study type: Interventional

The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to compensate for reduction in radiotherapy.

NCT ID: NCT02661503 Active, not recruiting - Clinical trials for Classical Hodgkin Lymphoma

HD21 for Advanced Stages

Start date: July 2016
Phase: Phase 3
Study type: Interventional

Primary objective of the trial is to demonstrate non-inferior efficacy of six cycles of BrECADD compared to six cycles of escalated BEACOPP, each followed by radiotherapy to PET-positive residual lesions ≥2.5 cm, in terms of progression free survival (efficacy objective). If non-inferior efficacy can be shown, the co-primary objective is to further demonstrate reduced toxicity of the BrECADD treatment compared to the escalated BEACOPP treatment measured by treatment related morbidity (TRMorbidity objective).